A new publication referencing glatiramer was released on November 6, 2026. The paper, titled "Off-label disease-modifying therapies for multiple sclerosis in low- and middle-income countries," appeared in the journal Multiple Sclerosis and Related Disorders.
The publication addresses the use of off-label disease-modifying therapies for multiple sclerosis in low- and middle-income countries. Glatiramer is approved and is referenced within this context.
This entry reflects the publication record only. No findings, outcomes, or efficacy data from the paper are detailed here. Readers interested in the full scope of the discussion should consult the publication directly through the listed source.
For general background on glatiramer, readers can refer to the compound overview.